Nurix Therapeutics Inc [NRIX] stock is trading at $26.27, up 4.16%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NRIX shares have gain 4.87% over the last week, with a monthly amount glided 13.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $35. Previously, Jefferies started tracking the stock with Buy rating on October 11, 2024, and set its price target to $41. Truist started tracking the stock assigning a Buy rating and suggested a price target of $36 on July 31, 2024. Barclays started tracking with a Overweight rating for this stock on March 09, 2023, and assigned it a price target of $20. In a note dated February 28, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $25 on this stock.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $4.22 and $26.43 over the past year. Currently, Wall Street analysts expect the stock to reach $32.2 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $26.27 at the most recent close of the market. An investor can expect a potential return of 22.57% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 56.42M for the trailing twelve months, which represents a drop of -31.84%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -3.13%, and Net Profit Margin reading is -3.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.63 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.28 points at the first support level, and at 24.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.17, and for the 2nd resistance point, it is at 28.06.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 5.28. Further, the Quick Ratio stands at 5.28, while the Cash Ratio is 1.15. Considering the valuation of this stock, the price to sales ratio is 32.98, the price to book ratio is 4.68.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Oct 14 ’24 when 3290.0 shares were sold. Chief Legal Officer, Ring Christine completed a deal on Oct 01 ’24 to sell 5760.0 shares. Meanwhile, Officer CHRISTINE RING bought 9050.0 shares on Oct 01 ’24.
